Oncology Alliance: Apeiron, CCRI and SIOPEN join forces against neuroblastoma

27-Jun-2011 - Sweden

Apeiron Biologics AG (Apeiron) announced the conclusion of an agreement with the Children's Cancer Research Institute (CCRI) and the European neuroblastoma Research Network (SIOPEN). Thereby, Apeiron obtains the rights to further develop, file for regulatory approval and market the antibody ch14.18. This monoclonal antibody exhibits therapeutic effect against high-risk neuroblastoma, an aggressive form of infant cancer. The antibody specifically targets the antigen GD2, a feature on the surface of neuroblastoma cells and thereby initiates an immune reaction against these cells.

As part of the agreement, Apeiron will provide substantial support for an ongoing European clinical phase III trial with ch14.18. Due to the limited number of clinical centers specializing in the treatment of high-risk neuroblastoma, Apeiron is considering marketing the therapy on its own.

Dr. Hans Loibner, CEO of Apeiron, commented on the successful completion of the agreement: "This novel form of collaboration with CCRI and SIOPEN is a milestone for Apeiron. These non-profit organizations have accomplished remarkable clinical development achievements which we can now complement with our industrial know-how. With this collaboration, we add a project to our portfolio that is both innovative and close to the market."

Professor Ruth Ladenstein, head of the coordination center for clinical studies at CCRI, senior physician at St. Anna Kinderspital and European president of SIOP said: "We are convinced to have found an ideal partner in Apeiron for our project. Together, we will take the final steps of development for an urgently needed therapy against high-risk neuroblastoma. By applying immune therapy and other treatment improvements, we hope to increase the chances of survival for children with high-risk neuroblastoma by 30%, thereby rendering future survival rates of 60-70% realistic."

Financial details were not disclosed.

Other news from the department science

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous